scholarly journals Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Cancer ◽  
2018 ◽  
Vol 124 (12) ◽  
pp. 2541-2551 ◽  
Author(s):  
Sonali M. Smith ◽  
James Godfrey ◽  
Kwang Woo Ahn ◽  
Alyssa DiGilio ◽  
Sairah Ahmed ◽  
...  
2009 ◽  
Vol 27 (3) ◽  
pp. 426-432 ◽  
Author(s):  
Kirsty J. Thomson ◽  
Emma C. Morris ◽  
Adrian Bloor ◽  
Gordon Cook ◽  
Don Milligan ◽  
...  

Purpose The role of allogeneic transplantation with reduced-intensity conditioning in diffuse large B-cell lymphoma (DLBCL) is currently unclear, with relatively little published data. We report the outcome of reduced-intensity transplantation (RIT) in a cohort of 48 consecutive patients with relapsed/refractory DLBCL (30 patients with de novo disease and 18 patients with transformed follicular lymphoma) who underwent transplantation with an alemtuzumab-containing regimen, with a median follow-up of 52 months. Patients and Methods Patients had experienced treatment failure with a median of five lines of prior therapy, including autologous transplantation in 69%, and 17% of patients were chemotherapy refractory at transplantation. Median age was 46 years, and 38% of patients had matched/mismatched unrelated donors. Conditioning was with alemtuzumab, fludarabine, and melphalan, and additional graft-versus-host disease (GVHD) prophylaxis was with cyclosporine. Results All patients were successfully engrafted. Only 17% of patients developed grade 2 to 4 acute GVHD, with 13% experiencing extensive chronic GVHD. Four-year estimated nonrelapse mortality was 32%, and relapse risk was 33%. Twelve patients received donor lymphocyte infusions ± chemoimmunotherapy for relapse, and five patients obtained durable remissions, giving current progression-free survival (PFS) and overall survival (OS) rates at 4 years of 48% and 47%, respectively. Patients who had chemotherapy-sensitive disease before RIT had current PFS and OS rates at 4 years of 55% and 54%, respectively. Chemotherapy-refractory patients had a poor outcome. Conclusion The encouraging survival rates with extended follow-up suggest a role for RIT in chemotherapy-sensitive relapsed DLBCL, even in patients who have previously experienced treatment failure with autologous transplantation. Future studies will be required to determine whether any subset of patients with relapsed DLBCL should be considered for RIT versus autologous transplantation.


2018 ◽  
Vol 5 (2) ◽  
Author(s):  
Maroun Sfeir ◽  
Marissa Walsh ◽  
Rossana Rosa ◽  
Laura Aragon ◽  
Sze Yan Liu ◽  
...  

Abstract Background Infections caused by Mycobacterium abscessus group strains are usually resistant to multiple antimicrobials and challenging to treat worldwide. We describe the risk factors, treatment, and clinical outcomes of patients in 2 large academic medical centers in the United States. Methods A retrospective cohort study of hospitalized adults with a positive culture for M. abscessus in Miami, Florida (January 1, 2011, to December 31, 2014). Demographics, comorbidities, the source of infection, antimicrobial susceptibilities, and clinical outcomes were analyzed. Early treatment failure was defined as death and/or infection relapse characterized either by persistent positive culture for M. abscessus within 12 weeks of treatment initiation and/or lack of radiographic improvement. Results One hundred eight patients were analyzed. The mean age was 50.81 ± 21.03 years, 57 (52.8%) were females, and 41 (38%) Hispanics. Eleven (10.2%) had end-stage renal disease, 34 (31.5%) were on immunosuppressive therapy, and 40% had chronic lung disease. Fifty-nine organisms (54.6%) were isolated in respiratory sources, 21 (19.4%) in blood, 10 (9.2%) skin and soft tissue, and 9 (8.3%) intra-abdominal. Antimicrobial susceptibility reports were available for 64 (59.3%) of the patients. Most of the isolates were susceptible to clarithromycin, amikacin, and tigecycline (93.8%, 93.8%, and 89.1%, respectively). None of the isolates were susceptible to trimethoprim/sulfamethoxazole, and only 1 (1.6%) was susceptible to ciprofloxacin. Thirty-six (33.3%) patients early failed treatment; of those, 17 (15.7%) died while hospitalized. On multivariate analysis, risk factors significantly associated with early treatment failure were disseminated infection (odds ratio [OR], 11.79; 95% confidence interval [CI], 1.53–81.69; P = .04), acute kidney injury (OR, 6.55; 95% CI, 2.4–31.25; P = .018), organ transplantation (OR, 2.37; 95% CI, 2.7–23.1; P = .005), immunosuppressive therapy (OR, 2.81; 95% CI, 1.6–21.4; P = .002), intravenous amikacin treatment (OR, 4.1; 95% CI, 0.9–21; P = .04), clarithromycin resistance (OR,79.5; 95% CI, 6.2–3717.1, P < .001), and presence of prosthetic device (OR, 5.43; 95% CI, 1.57–18.81; P = .008). Receiving macrolide treatment was found to be protective against early treatment failure (OR, 0.13; 95% CI, 0.002–1.8; P = .04). Conclusions Our cohort of 108 M. abscessus complex isolates in Miami, Florida, showed an in-hospital mortality of 15.7%. Most infections were respiratory. Clarithromycin and amikacin were the most likely agents to be susceptible in vitro. Resistance to fluoroquinolone and trimethoprim/sulfamethoxazole was highly common. Macrolide resistance, immunosuppression, and renal disease were significantly associated with early treatment failure.


2019 ◽  
Vol 79 (4) ◽  
pp. 332-340 ◽  
Author(s):  
Alexander Szubert ◽  
Sarah Lou Bailey ◽  
Graham S. Cooke ◽  
Tim Peto ◽  
Martin J. Llewelyn ◽  
...  

2019 ◽  
Vol 42 (4) ◽  
pp. 345-350
Author(s):  
Rosa T. van der Kaaij ◽  
Francine E.M. Voncken ◽  
Jolanda M. van Dieren ◽  
Petur Snaebjornsson ◽  
Catharina M. Korse ◽  
...  

Oncology ◽  
2009 ◽  
Vol 77 (2) ◽  
pp. 140-146 ◽  
Author(s):  
Laurenz Vormittag ◽  
Andreas Gleiss ◽  
Werner Scheithauer ◽  
Fritz Lang ◽  
Friedrich Laengle ◽  
...  

2009 ◽  
Vol 36 (11) ◽  
pp. 711-713 ◽  
Author(s):  
Katherine E. Bunge ◽  
Richard H. Beigi ◽  
Leslie A. Meyn ◽  
Sharon L. Hillier

2014 ◽  
Vol 58 (10) ◽  
pp. 5909-5915 ◽  
Author(s):  
Sabyasachi Das ◽  
Santanu Kar Mahapatra ◽  
Satyajit Tripathy ◽  
Sourav Chattopadhyay ◽  
Sandeep Kumar Dash ◽  
...  

ABSTRACTMalaria is a major public health problem in tropical and subtropical countries, including India. This study elucidates the cause of chloroquine treatment failure (forPlasmodium falciparuminfection) before the introduction of artemisinin combination therapy. One hundred twenty-six patients were randomized to chloroquine treatment, and the therapeutic efficacy was monitored from days 1 to 28. Anin vitrosusceptibility test was performed with all isolates. Parasitic DNA was isolated, followed by PCR and restriction digestion of different codons of thepfcrtgene (codons 72 to 76) and thepfmdr1gene (N86Y, Y184F, S1034C, N1042D, and D1246Y). Finally, sequencing was done to confirm the mutations. Forty-three (34.13%) early treatment failure cases and 16 (12.69%) late treatment failure cases were observed after chloroquine treatment.In vitrochloroquine resistance was found in 103 isolates (81.75%). Twenty-six (60.47%) early treatment failure cases and 6 (37.5%) late treatment failure cases were associated with the CVMNK-YYSNYallele (the underlined amino acids are those that were mutated). Moreover, the CVIEK-YYSNYallele was found in 8 early treatment failure (18.60%) and 2 late treatment failure (12.5%) cases. The presence of the wild-typepfcrt(CVMNK) andpfmdr1(YYSNY) double mutant allele in chloroquine-nonresponsive cases was quite uncommon.In vivochloroquine treatment failure andin vitrochloroquine resistance were strongly correlated with the CVMNK-YYSNYand CVIEK-YYSNYhaplotypes (P< 0.01).


Pneumologie ◽  
2018 ◽  
Vol 72 (S 01) ◽  
pp. S54-S54
Author(s):  
P Christopoulos ◽  
M Elsayed ◽  
V Endris ◽  
F Bozorgmehr ◽  
M Kirchner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document